PR Newswire Clinical TrialsOriginal article
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
ConferenceASC36_35 FDCASC36ASC35Positive
AI Analysis
Summary
Ascletis announced preclinical data for ASC36_35 FDC demonstrating superior weight loss compared to eloralintide/tirzepatide combination in a diet-induced obese animal model, with oral discussion at the 62nd EASD Annual Meeting. This represents early-stage preclinical research presented at an industry conference.
Outcome Details
Preclinical data presentation at EASD Annual Meeting showing superior weight loss of ASC36_35 FDC compared to eloralintide/tirzepatide combination in diet-induced obese animal model
Importance:5/10
Sentiment:
0.60
preclinical dataweight lossfixed-dose combinationconference presentationobesity
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 23, 2026 12:10 AM